Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Frontage HoldingsFGHQF 56 EV-to-EBIT is 21.77 as of Aug. 20, 2026, which is 28% below its 10-year median of 30.41. GuruFocus rates FGHQF with a GF Score™ of 56/100 and a GF Value™ of $0.23 (Significantly Undervalued). The stock has 8 warning signs investors should review. Among 368 Biotechnology companies, Frontage Holdings ranks worse than 57.88% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Frontage Holdings's Enterprise Value for the quarter that ended in Dec. 2025 was $393.5 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Frontage Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $19.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Frontage Holdings EV-to-EBIT Related Terms
Frontage Holdings EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Frontage Holdings's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Frontage Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Frontage Holdings EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Frontage Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Frontage Holdings's EV-to-EBIT falls into.
Frontage Holdings's current Enterprise Value is $416.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Frontage Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $19.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Frontage Holdings (FGHQF) has a EV-to-EBIT of 21.77 as of Aug. 20, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Frontage Holdings and its competitors. This is 28% below median its historical median of 30.41. Over the past decade, Frontage Holdings' EV-to-EBIT has ranged from 11.16 to 94.58. According to the industry distribution chart, Frontage Holdings ranks #213 out of 368 companies in the Biotechnology industry, placing it in the top 57.9%.
Is Frontage Holdings' EV-to-EBIT too high?
Frontage Holdings' current EV-to-EBIT of 21.77 is 28% below median its 10-year median of 30.41. Over the past 10 years, this metric has ranged from a low of 11.16 to a high of 94.58. The Biotechnology industry median EV-to-EBIT is 16.63. Frontage Holdings' value of 21.77 is 30.9% above this industry median. Based on the distribution chart, Frontage Holdings ranks #213 out of 368 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Frontage Holdings has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Frontage Holdings' EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Frontage Holdings ranks #213 out of 368 companies for EV-to-EBIT. This places Frontage Holdings in the lower half of its industry. The industry median EV-to-EBIT is 16.63. Frontage Holdings' value of 21.77 is 30.9% above this benchmark. Historically, Frontage Holdings' own EV-to-EBIT has ranged from 11.16 to 94.58 over the past decade. While the company's 10-year median is 30.41 vs. the industry median of 16.63, Frontage Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 16.63, based on 368 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Frontage Holdings's current EV-to-EBIT of 21.77 is 30.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Frontage Holdings and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 16.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Frontage Holdings's current EV-to-EBIT is 21.77, which is 28% below median its own 10-year median of 30.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Frontage Holdings stock overvalued right now?
Based on GuruFocus' analysis, Frontage Holdings (FGHQF) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.23, compared to a current price of $0.15 — trading 34.8% below its estimated fair value. The current EV-to-EBIT is 21.77, which is 28% below median its 10-year median of 30.41 and 30.9% above the Biotechnology industry median of 16.63. Frontage Holdings' overall GF Score™ is 56/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Frontage Holdings (FGHQF), the current EV-to-EBIT is 21.77 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Frontage Holdings (FGHQF) Overvalued in 2026?
Based on GuruFocus' analysis, Frontage Holdings stock appears to be undervalued.
The current stock price of $0.15 is trading 34.8% below its estimated GF Value™ of $0.23.
GuruFocus considers Frontage Holdings to be Significantly Undervalued.
Key valuation signals for FGHQF:
EV-to-EBIT: 21.77 (28% below median its 10-year median of 30.41)
GF Value™: $0.23 vs. price of $0.15 (34.8% below fair value)
Industry Position: 30.9% above the Biotechnology median (#213 of 368)
No single metric tells the full story. See the FGHQF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Frontage Holdings Corp provides laboratory and related services to pharmaceutical and agrochemical companies. Its segments include North America and Europe segment, including drug discovery, drug development, pharmaceutical product development and laboratory testing in the USA, Canada and Europe; and PRC segment, including drug discovery, drug development, pharmaceutical product development and laboratory testing in the PRC. It derives majority of the revenue from North America and Europe segment. Geographically majority of the revenue is derived from USA and Canada.
56GF Score
Get the complete analysis for FGHQF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FGHQF has been successfully added to your 
